This firm's average rating is Buy from 3 analysts. We provide trade advice to complement the prevailing
expert consensus on Apyx Medical. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time. The company has Profit Margin (PM) of
(58.14) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of
(81.99) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.82.
The successful prediction of Apyx Medical
stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published
stock prices of traded companies, such as Apyx Medical, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at
the intrinsic value of Apyx Medical based on Apyx Medical hews, social hype, general headline patterns, and widely used
predictive technical indicators. We also calculate exposure to Apyx Medical's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Apyx Medical's related companies.
Watch out for price decline
Please consider monitoring Apyx Medical on a daily basis if you are holding a position in it. Apyx Medical is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Apyx Medical stock to be traded above the $1 level to remain listed. If Apyx Medical stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
Use Technical Analysis to project Apyx expected Price
Apyx Medical technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Apyx Medical technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Apyx Medical trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions.
More Info...Apyx Medical Gross Profit
Apyx Medical Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Apyx Medical previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Apyx Medical Gross Profit growth over the last 10 years. Please check Apyx Medical's
gross profit and other
fundamental indicators for more details.
Details
The company reported the previous year's revenue of 27.6
M. Net Loss for the year was (16.05
M) with profit before overhead, payroll, taxes, and interest of 19.09
M.
| 2017 | 2018 | 2019 | 2020 (projected) |
Current Assets | 22.55 M | 89.83 M | 76.73 M | 82.79 M | Total Assets | 30.99 M | 95.93 M | 84.75 M | 68.18 M |
Cost of Revenue Breakdown
Apyx Medical Cost of Revenue yearly trend continues to be fairly stable with very little volatility. Cost of Revenue is likely to outpace its year average in 2020. Cost of Revenue usually refers to the aggregate cost of goods produced and sold and services rendered during the reporting period. Apyx Medical Cost of Revenue is fairly stable at the moment as compared to the past year. Apyx Medical reported Cost of Revenue of 9.14 Million in 2019
| 2013 | 14.46 Million |
| 2014 | 18.69 Million |
| 2015 | 16.96 Million |
| 2016 | 3.7 Million |
| 2017 | 3.28 Million |
| 2018 | 5.78 Million |
| 2019 | 9.14 Million |
| 2020 | 9.88 Million |
Apyx Medical showing appearance of lower volatility
Risk adjusted performance is down to 0.19. It may suggest a possible volatility slide. Apyx Medical is displaying above-average volatility over the selected time horizon. Investors should scrutinize Apyx Medical independently to ensure intended market timing strategies are aligned with expectations about Apyx Medical volatility.
Our Conclusion on Apyx Medical
While other entities within the medical devices industry are still a little expensive, even after the recent corrections, Apyx Medical may offer a potential longer-term growth to investors. The inconsistency in the assessment between current Apyx Medical valuation and our trade advice on Apyx Medical is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Apyx Medical.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Apyx Medical. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
